

# Hansa Medical

## **The board of directors' statement under Chapter 19, Section 22 of the Swedish Companies Act**

The board of directors has proposed that the annual general meeting to be held on May 29 2018 resolves to authorise the board of directors to acquire 391,503 own class C shares of Hansa Medical AB (publ). The board of directors considers, in view of what is stated below, that the resolution to acquire own shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, as well as the need for Hansa Medical to strengthen the balance sheet, liquidity and position as a whole. The board of directors has also taken into account the requirements of the group's business, scope and risk place on the group's equity requirement and need for the group to strengthen its balance sheet, liquidity and position as a whole.

### **Equity**

The board of directors considers that the equity of Hansa Medical will be of sufficient amount after the proposed acquisitions, taking into account the business, scope and the risks that the business is associated with and the current economic situation, historical development and forecasts for Hansa Medical as well as for the market.

### **Need of strengthening of the balance sheet, liquidity and position as a whole**

The board of directors has made a comprehensive assessment of Hansa Medical's financial position and its ability to, in the long term, fulfill its undertakings. As stated in Hansa Medical's annual report for the financial year of 2017, the non-restricted equity of Hansa Medical as per December 31, 2017 was SEK 587,320,116.

The proposed acquisitions does not affect Hansa Medical's ability to in due time fulfill its present and anticipated financial obligations or Hansa Medical's ability to implement planned investments.

The board of directors has also considered other known matters that may affect Hansa Medical's financial position and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions unjustifiable has been identified during such analysis.

Lund, 24 April 2018  
**Hansa Medical AB (publ)**  
The board of directors